LRRK2 and Parkinson disease: LRRK2 is considered a very attractive target for therapeutic development, and, in fact, several potent and selective LRRK2 kinase inhibitors have been developed and are considered one of the major disease-modifying therapeutic strategies for PD (Taymans and Greggio, 2016).